--- title: "Suboxone Tooth Decay Lawsuit: Dental Injury Claims" url: https://www.masstortmarketingagency.com/blogs/suboxone-tooth-decay-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/suboxone-tooth-decay-lawsuit published: 2026-01-20 modified: 2026-01-20 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | How Suboxone sublingual film causes severe dental decay and tooth loss, the FDA's June 2022 Drug Safety Communication (305 adverse events, 131 serious), Indivior's failure-to-warn exposure, screening criteria, damages tiers, litigation strategies, and qualifying claimants for PI practices. keywords: - Suboxone tooth decay lawsuit - buprenorphine dental damage - FDA Drug Safety Communication 2022 - Indivior failure to warn - sublingual film acid erosion - Suboxone MDL license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Suboxone tooth decay lawsuit: dental injury claims > **Quick answer.** Suboxone sublingual film (buprenorphine/naloxone), made by Indivior (formerly Reckitt Benckiser Pharmaceuticals), is linked to severe tooth decay, fractures, infections, and tooth loss. On June 22, 2022, the FDA issued a Drug Safety Communication reporting 305 dental adverse-event cases — 131 of them serious — and required new label warnings. Plaintiffs allege Indivior knew of the dental risks (acidic film pH plus buprenorphine-induced dry mouth) and failed to warn; cases are consolidated in a federal MDL with bellwether preparation underway. Key stats: 305 FDA adverse events; FDA warning issued 2022; 131 serious cases reported; projected case values in the millions-plus tier overall. ## Understanding the Suboxone tooth decay lawsuit Suboxone, a sublingual film containing buprenorphine and naloxone, has been one of the most widely prescribed medications for opioid use disorder (OUD) in the United States. A growing body of evidence — culminating in the June 2022 FDA Drug Safety Communication — shows that Suboxone and other buprenorphine-containing sublingual and buccal products cause severe dental problems, including tooth decay, cavities, oral infections, and complete tooth loss. Patients are pursuing failure-to-warn claims against Indivior. The FDA communication is the cornerstone of the litigation: it confirms the causal relationship, demonstrates inadequate prior labeling, and establishes a clear timeline showing patients were not warned. ## How Suboxone sublingual film causes severe dental decay ### The acidic pH mechanism The film's formulation has a pH well below the critical threshold (approximately 5.5) at which tooth enamel demineralizes. Dissolving the film under the tongue or against the cheek creates an acidic oral environment that erodes enamel and exposes dentin to bacterial invasion. Patients typically dose once or twice daily, with several minutes of dissolution per dose — repeated, prolonged acid exposure over months and years of daily use. ### Reduced salivary flow and dry mouth Buprenorphine reduces salivary flow (xerostomia). Saliva neutralizes acids, washes away food particles and bacteria, supplies remineralizing minerals, and carries antimicrobial enzymes. The combination of direct acid exposure and lost salivary protection is a two-pronged assault that explains why Suboxone-associated damage is more severe and widespread than other common causes of dental erosion. ### Pattern of dental injuries Damage characteristically begins on the lingual (tongue-side) surfaces of lower teeth and palatal surfaces of upper teeth — the areas in contact with the dissolving film. Decay is often circumferential at the gum line, affects multiple teeth simultaneously, and can progress remarkably fast. ## The FDA Drug Safety Communication: June 2022 On June 22, 2022, the FDA issued "FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain." The agency reported 305 cases of dental adverse events with buprenorphine medicines dissolved in the mouth, including 131 classified as serious: dental caries, tooth fractures, tooth loss, and procedures including extractions, root canals, implants, and dentures. Dental problems were reported even in patients with no prior dental issues, with time to onset ranging from two weeks to years after starting treatment — directly supporting plaintiffs' causation theory. The FDA then required manufacturers to add dental-risk warnings to labels: information on caries, erosion, and tooth loss; a recommended dental examination before starting treatment; regular dental visits and prompt reporting of problems; and an instruction not to brush teeth immediately after the film dissolves. ## Indivior: the manufacturer and its failure to warn Indivior PLC (originally a division of Reckitt Benckiser) developed the film formulation as a successor to the original Suboxone tablet, transitioning the market through strategic patent management and marketing. In 2020, Indivior Inc. (the U.S. subsidiary) pleaded guilty to a federal felony charge related to fraudulent marketing of Suboxone Film, admitting misleading claims about the film's safety relative to tablets — a record relevant to punitive-damages arguments. Plaintiffs allege Indivior knew or should have known of dental risks well before 2022: the film's acidic pH was known from development; oral acid effects on enamel are well established in dental science; FDA adverse-event reports documented dental problems; and buprenorphine's salivary effects were documented in the pharmacological literature. ## Who qualifies: screening criteria Core requirements: - **Suboxone Film prescription** — claims focus primarily on the film, not the original tablet. - **Dental injury** after beginning treatment: decay/cavities, fractures, tooth loss, infections/abscesses, and/or significant procedures. - **Temporal relationship** — damage developed after starting Suboxone Film; documented good prior dental health is especially strong. - **Minimum injury threshold** — typically multiple affected teeth, extractions, root canals, implants, or dentures. Strongest profiles: documented good pre-Suboxone dental health, multiple extractions or dentures/implants, acid-erosion damage pattern, extended duration of use, patients under 50 (where severe tooth loss is atypical), and well-documented record progression. ### Projected case value tiers | Case tier | Projected range | Profile | |---|---|---| | Tier 1 (Most severe) | Mid-to-high five to low six figures | Full mouth extraction, complete dentures, extensive implants | | Tier 2 (Significant) | Mid-range | Multiple extractions, partial dentures, multiple implants | | Tier 3 (Moderate) | Lower tier | Multiple restorations, root canals, some extractions | ## Damages - **Economic:** emergency dental treatment; extractions (hundreds to over $1,000 per tooth); root canals; implants (typically $3,000–$6,000 per implant); bridges and crowns; full or partial dentures; bone grafting before implant placement; and lifetime maintenance and replacement of prosthetics. - **Non-economic:** pain and suffering from decay, infection, and surgery; embarrassment from tooth loss; dietary limitations; speech difficulties; and the psychological impact of disfigurement in a population already managing opioid recovery — a betrayal-of-trust narrative juries may find compelling. - **Punitive:** Indivior's criminal conviction for fraudulent marketing plus alleged internal knowledge of dental risks could support willful, wanton, or reckless conduct findings in permitting jurisdictions. ## Building a strong case Record collection: pharmacy dispensing and prescriber records confirming Suboxone Film, pre-Suboxone dental records (baseline health), dental records during and after use showing progression, treatment records, and OUD treatment records. Expert categories: forensic dentists (acid-erosion pattern), pharmacologists (pH and salivary mechanisms), regulatory experts (labeling adequacy and the 2022 FDA communication), dental economists or life care planners (current and future costs), and addiction medicine specialists (treatment-landscape context). ## The opioid crisis context Medication-assisted treatment with Suboxone is recognized as the gold standard for managing opioid use disorder. Patients who turned to Suboxone were rebuilding their lives; failing to warn them about a foreseeable, preventable complication undermined recovery with pain, embarrassment, and financial hardship. ## Statute of limitations Analysis turns on the date of injury, the discovery rule, and the state limitations period. Because the FDA's warning did not issue until June 2022, many patients did not connect their dental problems to Suboxone until after that date — the discovery rule may toll the deadline in many cases, but jurisdiction-specific analysis is required for every claim. ## Suboxone in the mass tort landscape Like the Depo-Provera meningioma litigation (https://www.masstortmarketingagency.com/mass-tort-leads/depo-provera), it involves a widely prescribed medication with an undisclosed known risk; like the NEC baby formula litigation (https://www.masstortmarketingagency.com/mass-tort-leads/nec), it involves a vulnerable population relying on manufacturer safety representations. A distinguishing feature: the injury is visible and tangible — photographs of dental destruction and before-and-after records create a compelling courtroom narrative. ## Frequently asked questions ### What dental problems does Suboxone cause? Severe tooth decay (cavities), tooth erosion, tooth fractures, dental infections and abscesses, tooth loss, and the need for extractions, root canals, implants, and dentures. The FDA's June 2022 Drug Safety Communication confirmed these risks. ### How does Suboxone damage teeth? Two mechanisms: the film's acidic pH directly erodes enamel as it dissolves against the teeth, and buprenorphine reduces salivary flow, removing saliva's protective and remineralizing effects. Together they create conditions for rapid, severe decay. ### Who qualifies for a Suboxone tooth decay lawsuit? Patients prescribed Suboxone sublingual film who experienced significant dental problems during or after use. Strongest cases: documented good dental health before Suboxone, multiple affected teeth, extractions or major procedures, and a clear timeline linking use to damage onset. ### Did the FDA warn about Suboxone dental problems? Yes. On June 22, 2022, the FDA issued a Drug Safety Communication on dental problems with buprenorphine medicines dissolved in the mouth and required manufacturers to add dental warnings to labels. Before that, Suboxone's labeling did not warn of dental damage. ### What is the current status of Suboxone tooth decay litigation? Cases are consolidated in a federal MDL for coordinated pretrial proceedings, progressing through discovery and expert disclosure with bellwether trial preparation underway. The inventory continues to grow as more patients connect their dental problems to Suboxone. ### How much could a Suboxone tooth decay case be worth? No global settlement has been reached. Values depend on damage severity, treatment cost, and bellwether outcomes. Patients requiring full mouth extraction and dentures or extensive implant work are expected to occupy the highest value tier. ### Can I file a Suboxone lawsuit if I still use Suboxone? Yes. Continued use does not bar claims for dental injuries already sustained. Patients should not stop Suboxone without medical guidance, as abrupt discontinuation can trigger opioid withdrawal. ### How can my law firm acquire qualified Suboxone claimants? Digital marketing targeting OUD treatment communities, outreach to addiction medicine practices, partnerships with dental professionals treating Suboxone patients, and specialized lead-generation agencies that pre-screen against qualification criteria — see https://www.masstortmarketingagency.com/mass-tort-leads/suboxone. --- *Published by Mass Tort Agency. Canonical URL: https://www.masstortmarketingagency.com/blogs/suboxone-tooth-decay-lawsuit*